Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular ...(targeting used by the PSD allows for ane...),Health

Date:9/19/2008

targeting used by the PSD allows for an extended observation period, dependent only upon the environmental support available for the cells. Further, non-invasive electrical stimulation can be done without causing damage to the cells while optical targeting enables highly controlled depolarization of only target cells. The PSD can also be used in place of pharmacological agonist stimulation, which does not allow for specific cell targeting and/or rapid repetitive depolarization, where such experimental capabilities would be desirable.

The PSD system controller is a fully contained, easy to use electronics base that readily fits into any bench-top environment. Cells for experimentation are grown on the silicon PSD substrates that fit in industry standard 24 well plates for cell culture and storage, and are then mounted onto the reusable PSD experimental chamber for live cell observation using any standard up-right microscope. Current promotion bundles including the PSD controller, experimental chambers, and cell culture substrates begin at $3,550.00.

Advancing the frontiers of excitable cell research, such as in neurons and muscle cells will serve to further our understanding of the mechanisms underlying cellular structure/function relationships. Additionally, it will enable scientists to better elucidate how these mechanisms go awry during disease states and potentially how to better address (and/or prevent) the disease state (and/or injury) following onset. Further, the diagnostic testing and drug discovery potential of the PSD will provide insights into the identification and development of new therapeutics.

About Neurosilicon

Neurosilicon develops novel brain-computing interfaces to expand the scientific understanding of the human brain and to revolutionize and improve the effectiveness of drug discovery. The company's flagship product, the Photoconductive Stimulation Device (PSD) stimulates excitable cells in a precise and controllabl
'/>"/>

SOURCE Neurosilicon Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Omeros and The Parkinsons Institute and Clinical Center Enter into a Collaboration Agreement to Evaluate Novel Target for the Treatment of Movement Disorders
2. Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R)
3. Novel Compound Shows Promise for Treatment of Alcoholism
4. Major State Grant Accelerates Research and Development of Novel Cancer Therapy
5. Volcanos VH(R) IVUS Technology Used in Imaging Study of GlaxoSmithKlines Novel Investigational Compound, Darapladib
6. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for the Use of Novel Compounds as Potential Treatment for Neurodegenerative Diseases
7. Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
8. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
9. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
10. Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate
11. Study Reveals Novel LCD Solution Provides Significant Benefits Versus Calcipotriol In Treatment Of Moderate Psoriasis